California Biomedical Industry - California Healthcare Institute

More documents

Recommendations

Info

Device advancementsLeading the charge to reduce the spread of infections inhealthcare settingsIn March 2010, BD launched a new surveillance system that generates realtimeinformation designed to reduce the spread of infections. The BD ProtectInfection Surveillance and Data Management System is a portfolio of healthcaremanagement software solutions that tracks infections and helps prevent theirtransmission at three levels – from patient to patient, between patients andhealthcare workers, and from community sources to healthcare settings.The software provides real-time tracking and analysis of potential infection-relatedevents to improve infection prevention workflow, communications and responsetime. Robust report capability enables analysis of infection rates, evaluation ofpatient risk factors, monitoring of preventive processes, and measurement ofprogress toward infection prevention and patient safety goals.The Centers for Disease Control and Prevention (CDC) has identified healthcareassociatedinfections (HAIs) as one of the top 10 causes of death in the UnitedStates. Designed by CDC-trained epidemiologists, the BD Protect system addressesmultiple issues confronting healthcare administrators and public health officers,including the transmission of multidrug-resistant organisms in healthcare settingsand escalating costs related to HAIs.The portfolio includes three modules. BD Protect Infection Prevention targetsreduction of HAIs in patients. BD Protect Healthcare Worker Safety monitorsemployee vaccinations, testing, in-service education, injuries and illnessesto protect both employees and patients. BD Protect Syndromic Surveillancecontinuously analyzes emergency department patient data for reportable diseasesand symptoms that could signal a possible community outbreak. It also can be usedat a health department to collect and analyze community-wide data from multiplehospitals.Diagnostics advancesImproved Group BStreptococcus diagnostics fornewborn healthIn June 2010, BD received 510(k)clearance from the FDA to market theBD MAXTM GBS Assay for Group BStreptococcus (GBS) on the BD MAXSystem.GBS remains one of the leading causesof morbidity and mortality amongnewborns, with maternal colonizationserving as a major risk factor for earlyonset GBS disease. However, GBS ispreventable with antibiotics duringlabor, which prevents transmissionfrom mother to infant. The CDCrecommends universal prenatalscreening for GBS colonization andintrapartum chemoprophylaxis forcolonized mothers in order to preventtransmission to infants. The currentstandard of care for preventing neonatalGBS disease is screening pregnantwomen at 35 to 37 weeks of gestationusing culture methods, which arelimited by sensitivity, turnaroundtime and the need for highly trainedtechnologists to interpret the results.The BD MAX GBS assay on the BDMAX System represents a significantadvance in neonatal healthcare bystreamlining the GBS screening processand addressing the limitations ofcurrent culture methods by providingrapid, objective results. With no visualinterpretation required, the BD MAXGBS assay identifies GBS in just overan hour, which can help ensure thatcolonization status is available in thecase of preterm delivery. By automatingsample lysis through polymerase chainreaction detection, the BD MAX Systemoffers walkaway convenience for up to24 samples in approximately two and ahalf hours.36 | California Biomedical Industry 2011 Report
Researcher profileDr. Samuel So addresses an epidemic of a preventable diseaseCalifornia Hapatitis B & CFiguresUp to 5.3 million Americans – 2 percentof the U.S. population – are living withchronic HBV or HCV.Viral hepatitis is the fourth leadinginfectious cause of death.California is home to about 40 percent(or 6.7 million) of the nation’s AsianAmerican population and 150,000people of Pacific Islander ancestry.San Francisco and Santa Claracounties experience some of thehighest rates of chronic HBV and livercancer in the United States.Unaware that they have been infectedwith hepatitis B, one of 10 Asians andPacific Islanders lives with the chronicinfection — the leading cause of livercancer.Liver failure from chronic hepatitis C isone of the most common reasons forliver transplants in the United States.In 2007 alone, HBV and HCV-relatedhospitalization costs in Californiatotaled $2 billion.Samuel So, MD, FACS, Director of theAsian Liver Center, Director of theLiver Cancer Program, and the LiuHac Minh Professor of Surgery at theStanford University School of Medicine,was recruited to California as a livertransplant surgeon, an ambition he hadworked hard to fulfill. Yet he was notfar into his practice in the Golden Statewhen he found his true calling.“We were spending hundreds ofthousands of dollars to save one life[through a liver transplant],” he said,“when we could spend far less to savethousands and thousands of lives.”He explained that the preponderanceof his transplant patients had chronichepatitis B virus (HBV), an infection forwhich there has been a safe, effective,and inexpensive vaccine for morethan 30 years. And, yet, an estimated800,000 to 1.4 million Americans havechronic hepatitis B. Approximately onein 10 Americans of Asian and PacificIslander descent have chronic HBVinfection as compared to one in 1,000 ofwhite Americans.One challenge to stemming thespread of HBV is that many peopleare symptom free and do not knowthey have the disease until they havesignificant liver damage. Anotherchallenge, especially in the U.S., isthat neither at-risk groups nor theirhealthcare providers recognize that theyshould be screened and vaccinated forHBV.The at-risk groups include individualsborn in countries with high incidencesof HBV and hepatitis C (HCV), andanyone who might be exposed tocontaminated blood by handlingneedles or other sharp objects. Thesecond group includes healthcareproviders, tattoo artists or clients, andillegal drug users. Individuals born inthe U.S. before 1990, when HBV vaccinewas added to the infant immunizationschedule, and whose mothers wereborn in another country, also should bescreened, So said.Screening for the disease requires asimple blood test, “like the one theRed Cross uses before accepting blooddonations,” So said. In fact, beingturned away at the Blood Mobile ismany patients’ first indication that theyhave a hepatitis infection. If the bloodtest comes back negative, the patientshould be vaccinated. If the test comesback positive, the patient should bescreened periodically for changes in hisor her liver health. People with chronicHBV should also protect their livers bynot drinking alcohol and take measuresto ensure that they do not infect others.To raise awareness of HBV and livercancer, especially among the AsianAmerican communities in the Bay Area,So founded and became director of theAsian Liver Center at Stanford Schoolof Medicine in 1996. The center focuseson outreach and education, researchand advocacy, and it is reaching wideraudiences every year. For instance,the center’s Jade Ribbon Campaign isworking with Asian communities thelength of California as well as across thecountry and around the world.The center is drawing on the energyand creativity of youth members withprograms such as the Jade RibbonYouth Council (JRYC), which movesHBV awareness and discussion intohomes, churches and other gatheringplaces. One cultural factor in the fightagainst HBV is that having the diseaseis a stigma in Asian countries. Youngfamily members who have accurateinformation and a passion to makea difference in the health of theircommunities can change perceptionsand behaviors, So said.On the policy front, So has been anactive supporter of state legislation thatwould help eradicate the disease here.He has worked with AssemblywomanFiona Ma in drafting a couple ofHBV-related bills. Ma, who herselfhas chronic HBV, in 2008 introducedCalifornia Biomedical Industry 2011 Report | 37
Page 5 and 6: In analyzing California’s biomedi
Page 7 and 8: scans from patients a continent awa
Page 11 and 12: Figure 1: Distribution of employmen
Page 13 and 14: Figure 8: California biomedical ind
Page 15 and 16: state operations (Figure 16). For t
Page 17 and 18: FigureFigure20.14:VentureVenturecap
Page 19 and 20: Survey participants also rankedfede
Page 21 and 22: State tax credits to support the gr
Page 23 and 24: of competing products worldwide wer
Page 25 and 26: Sacramento area shows growth and pr
Page 27 and 28: Figure 38: California has largest c
Page 29 and 30: OncologyCancers in California, 2010
Page 31 and 32: Diagnostics advancementsNew ovarian
Page 33 and 34: Patient profileBill Walton striding
Page 35 and 36: families themselves; to institution
Page 37: HIV and AIDS statisticsby stateAn e
Page 41 and 42: Immunology and inflammatory disorde
Page 43 and 44: Cardiovascular diseaseAs is the cas
Page 45 and 46: Diabetes and metabolic disordersPha
Page 47 and 48: Researcher profileFrancine R. Kaufm
Page 49 and 50: ___________________________________
Page 51 and 52: Figure 41. Since 2007 there has bee
Page 53 and 54: time that wireless technologies can
Page 55: Workforce developmentA thriving ent
Page 58 and 59: access and quality while addressing
Page 60 and 61: California State University SystemR
Page 62 and 63: StanfordSummer research program re-
Page 64 and 65: Bellush said that bringing BiotechA
Page 66 and 67: Amylin PharmaceuticalsSummer Intern
Page 68 and 69: Bringing Science to Life in OurScho
Page 70 and 71: the private sector. NIH funding ena
Page 72 and 73: Small Business Administrationprogra
Page 74 and 75: Promising UC research fundedby NIHB
Page 76 and 77: University of Southern California
Page 78 and 79: Stanford UniversitySince its foundi
Page 80 and 81: The Scripps Research Institute (TSR
Page 82 and 83: Sanford-Burnham Medical Research In
Page 85 and 86: small biotechnology companies as th
Page 87 and 88: The Salk Institute celebrates 50 ye
Page 89 and 90:
Bayer HealthCare establishes U.S.In
Page 91:
UC Merced: Addressing healthcare di
Page 95 and 96:
Executive profileDr. Ed Holmes, Pre
Page 97 and 98:
“Only by lowering the barriers to
Page 99 and 100:
Researcher profileHans Keirstead, P
Page 101 and 102:
Special sectionPharmaceuticals in t
Page 103 and 104:
MethodologyEmployment, Wages, andIn
Page 105:
NIH GrantsDataData for this analysi
Page 108:
Report authors hereDavid L. Gollahe
show all

California Biomedical Industry - California Healthcare Institute

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?